MoonLake Immunotherapeutics
MLTX
MLTX
33 hedge funds and large institutions have $396M invested in MoonLake Immunotherapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
2.96% less ownership
Funds ownership: 99.8% → 96.84% (-3%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Holders
33
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$9.2M | |
| 2 | +$4.26M | |
| 3 | +$2.1M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.58M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.24M |
Top Sellers
| 1 | -$6.65M | |
| 2 | -$2.6M | |
| 3 | -$2.33M | |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.49M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$491K |